SHSabine Hermans

Sabine Hermans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sabine Hermans has a total of 445 co-authors. Here are the top co-authors by number of shared publications:

  • Robin Wood

    Desmond Tutu HIV Centre, P.O. Box 13801, Mowbray, 7705 Cape Town, South Africa; Institute of Infectious Diseases and Molecular Medicine, University of Cape Town Faculty of Health Sciences, Anzio Rd, Observatory, Cape Town 7925, South Africa

    12 shared publications
  • Frank van Leth

    Department of Health Sciences, Vrij Universiteit Amsterdam; the Netherlands; Amsterdam Public Health Research Institute, Amsterdam, the Netherlands

    7 shared publications
  • Yukari C. Manabe

    Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda

    5 shared publications
  • Yukari Carol Manabe

    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland

    5 shared publications
  • Barbara Castelnuovo

    Infectious Diseases Institute, Makerere University College of Health Sciences, P.O. Box 22418, Kampala, Uganda

    4 shared publications
  • Frank Cobelens

    University of Amsterdam, Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands

    4 shared publications

Latest Publications

  • Open Access

    Prevalence of asymptomatic pulmonary tuberculosis by bacteriological status and the associated risk factors. A secondary data analysis of the Uganda national tuberculosis prevalence survey, 2014-2015

    by Aldomoro Burua, Bruce Kirenga, Deus Lukoye, Simon Walusimbi, Stavia Turyahabwe, Henry Luzze, Frank Cobelens, Sabine Hermans

    BackgroundNearly half of people with tuberculosis (TB) in high incidence settings have asymptomatic disease. Analyzing the different types of asymptomatic TB and the risk factors could inform TB policy and programmatic interventions. We determined the prevalence and risk factors for asymptomatic TB in Uganda, a high TB/HIV burdened country. MethodsWe analyzed secondary data from the national tuberculosis prevalence survey (2014-2015). We defined asymptomatic TB based on the WHO definition: Asymptomatic TB bacteriologically confirmed (aTB-C) and unconfirmed (aTB-U), applying the symptom screen criteria: absence of cough >=2 weeks. We explored two other definitions: absence of cough of any duration, and absence of any TB symptom. Multivariable regression analysis was performed to identify factors associated with asymptomatic TB for each definition.ResultsOf the 41,003 participants data analyzed, 80 (41.9%) had asymptomatic bacteriologically confirmed TB defined as “absence of persistent cough >=2 weeks” while 111 (58.1%) had asymptomatic bacteriologically unconfirmed TB. The prevalence of aTB-C based on “absence of cough >=2 weeks” was 196 (95%CI 157-244) and that of aTB-U was 281 (95%CI 233-338) /100,000 population. Past smoking and urban residence were associated with increased prevalence of aTB-C, while age >55 years and past TB treatment were associated with aTB-U.Conclusion and recommendationsA substantial proportion of the prevalent TB patients in Uganda have asymptomatic TB and the determinants of aTB-C and aTB-U appear different. Targeted approaches in the specified population groups incorporating strategies beyond symptom screening are required for early detection of asymptomatic TB and advance TB control efforts.

  • Feasibility, challenges, and lessons learned in implementing antiretroviral adherence club models in Northern Tanzania

    by Ramadhani Abdul, Lukas Van Duffel, Giulia Martelli, Edda Ndyamukama Joel, Joyce Zacharia Misesemo, Tobias F. Rinke de Wit, Sayoki Mfinanga, Anton Pozniak, Sabine Hermans

    Introduction: In Tanzania, nearly 1.6 million adults were living with HIV in 2022, with an HIV prevalence rate of 4.4%. We piloted community health worker-managed adherence clubs in two clinics in Shinyanga, Tanzania. We previously demonstrated better stability in care and improved treatment adherence following the establishment of clubs. This study evaluated referral back to the facility, feasibility, and challenges to inform potential scale-up.Method: The study included clubs from two clinics between July 2018 and September 2019, Ngokolo (13 clubs) and Bugisi (33 clubs), all located in the Shinyanga region. Clinicians invited stable clients to join an AC if they met eligibility criteria. Logistic regression models identified factors associated with the likelihood of clients' referral back to the facilitiesResults: The setup of the adherence clubs was feasible and successful. In one year, 46 clubs with 617 clients were established. Thirty-eight clients (6.3 %) were referred back to the clinics. Factors associated with being referred back were lower age (below 25 compared to above), having ever missed AC visits, and a rural site. Challenges included start-up problems with wrongful enrolments, the need for additional staff to facilitate the club model, the duplication of data collection tools, and the need for youth-friendly adherence clubs.Conclusion: Task shifting to community health workers to manage the clubs was successful. Despite its success, it required a higher level of organisation, particularly during the setup phase. These findings support the revision of the National HIV guideline to formally integrate community health worker-led adherence clubs, ensuring scalability and sustainability.

  • Open Access

    Research ethics and integrity challenges in accelerated clinical trials, an interview study

    by Clàudia Pallisé Perelló, Giulia Inguaggiato, Loïs van Eck, Hanna K. de Jong, Sabine M. Hermans, Martin P. Grobusch, Mariëtte van Den Hoven, Natalie Evans

    Accelerated clinical trials for drugs and vaccines during global health crises allow for rapid access but pose research ethics and integrity challenges. Un


  • Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM)

    by Lucía Carratalà Castro, Shilzia Munguambe, Alexander Kay, Willy Ssengooba, Durbbin Mulengwa, Sozinho Acácio, Joanna Ehrlich, Andrew R DiNardo, Anca Vasiliu, Abigail Seeger, et al.

    New diagnostic tests and alternative samples to diagnose tuberculosis in children are needed to tackle the diagnostic gap of pediatric tuberculosis. The Determine TB LAM Ag test in urine demonstrated sensitivity of 15.9% and specificity of 90.6%. Collecting the urine in adhesive bag was an independent risk factor for positivity (odds ratio, 11.38; P < .01).

  • Projecting the Impact and Costs of Near Point-of-Care Tuberculosis Screening Assays in Community-based Active Case Finding

    by Jason R Andrews, Emily A Kendall, Adithya Cattamanchi, Claudia M Denkinger, Payam Nahid, Sourya Shrestha, Florian M Marx, David Dowdy, Sabine Hermans, Frank Cobelens

    Background: Community-based active case finding (ACF) may reduce tuberculosis incidence and mortality but is not widely implemented due to resource constraints. How novel screening test characteristics would affect the impact and costs of ACF strategies is not clear. Methods: We developed mathematical models of tuberculosis natural history and transmission, calibrated to data from 3 high tuberculosis burden countries (India, Vietnam, and the Philippines) and simulated the impact of annual community-based ACF programs. We compared annual screening, with or without an initial symptom screen, for 10 years with 2 hypothetical screening assays based on target product profile minimum targets: a low complexity (reaches 60% of the population) test with high sensitivity (90%) and moderate specificity (80%) costing $3; and a near point-of-care (reaches 80% of the population) test with moderate sensitivity (55%) and high specificity (98%) costing $2. We projected reductions in tuberculosis incidence, mortality, and costs under each scenario. Results: Annual screening with a low-complexity, high-sensitivity screening assay was projected to reduce tuberculosis mortality by 24%–38%, at an annual cost of $5.04–$5.83 per capita. Annual screening with a near-point-of-care, moderate-sensitivity assay was projected to achieve comparable reductions in mortality (24%–42%) at $3.49–$3.63 per capita. Symptom-based screening would yield more modest reductions in tuberculosis mortality (17%–24%) at an annual cost of around $1 per capita. Conclusions: Near point-of-care, moderate-sensitivity screening assays for tuberculosis could achieve substantial impact on tuberculosis mortality—equivalent to that of high-sensitivity assays and at lower cost—if they can be performed at scale in community settings.


  • Open Access

    Triage test for all-oral drug-resistant tuberculosis (DR-TB) regimen: a phase IV study to assess effectiveness, feasibility, acceptability and cost-effectiveness of the Xpert MTB/XDR assay for rapid triage and treatment of DR-TB

    by Kogieleum Naidoo, Anushka Naidoo, Alash'LE G Abimiku, Everdina W Tiemersma, Agnes Gebhard, Sabine M Hermans, Derek J Sloan, Morten Ruhwald, Sophia B Georghiou, Evaezi Okpokoro, et al.

    Introduction: The TriAD study will assess the Xpert MTB/XDR (Xpert XDR; Cepheid) assay to detect tuberculosis (TB) drug resistance in sputum testing positive for TB to rapidly triage and treat patients with a short all-oral treatment regimen. Methods and analysis: In this study, approximately 4800 Xpert MTB/RIF or Ultra MTB-positive patients (irrespective of rifampicin (RIF) resistance (RR) status) from several clinical sites across South Africa, Nigeria and Ethiopia will be enrolled over 18–24 months and followed-up for approximately 6 months post-TB treatment completion. Participants will be enrolled into one of two cohorts based on Xpert MTB/RIF and Xpert XDR results: Mycobacterium tuberculosis ( M.tb ) positive participants with RR in Cohort 1 (n=880) and M.tb positive RIF susceptible TB patients with isoniazid mono-resistance irrespective of presence of resistance to fluoroquinolones, second-line injectable drugs or ethionamide in Cohort 2 (n=400). Cohort 1 will be compared with historical cohorts from each implementing sites. The primary study outcomes include time to initiation of an appropriate treatment regimen by resistance profile and the proportion of patients with favourable treatment outcomes compared with historical cohorts from each of the implementing sites. Secondary outcomes include feasibility, acceptability and cost-effectiveness of this approach to inform policies and guidelines for programmatic implementation of this triage and treat model for drug-resistant tuberculosis management. Utility of the tuberculosis molecular bacterial load assay (TB-MBLA) for real-time treatment response assessment will also be evaluated. Ethics and dissemination: The University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC) and local research committees have provided ethical review and approval (BREC/00002654/2021, HREC 210805, NHREC/01/01/2007 and EPHI-IRB-459–2022). The South African Health Products Regulatory Authority (SAHPRA) have granted regulatory approval for the TRiAD Study (SAHPRA MD20211001). Trial results will be disseminated through conference presentations, peer-reviewed publications and the clinical trial registry. Trial registration number: Clinicaltrials.gov; Trial registration number: NCT05175794 ; South African National Clinical Trials Register (SANCTR DOH-27-012022-4720)


  • Open Access

    Neighbourhood factors and tuberculosis incidence in Cape Town: A negative binomial regression and spatial analysis

    by M. Molemans, L. Kayaert, Q. Olislagers, S. Abrahams, N. Berkowitz, E. Mohr‐Holland, D. McKelly, R. Wood, F. van Leth, S. Hermans

    Objectives: Although the link between poverty and tuberculosis (TB) is widely recognised, limited studies have investigated the association between neighbourhood factors and TB incidence. Since the factors influencing different episodes of TB might be different, this study focused on the first episode of TB disease (first‐episode TB).Methods: All first episodes in previously linked and geocoded TB notification data from 2007 to 2015 in Cape Town, South Africa, were aggregated at the neighbourhood level and merged with the 2011 census data. We conducted an ecological study to assess the association between neighbourhood incidence of first‐episode TB and neighbourhood factors (total TB burden [all episodes] in the previous year, socioeconomic index, mean household size, mean age, and percentage males) using a negative binomial regression. We also examined the presence of hotspots in neighbourhood TB incidence with the Global Moran's I statistic and assessed spatial dependency in the association between neighbourhood factors and TB incidence using a spatial lag model.Results: The study included 684 neighbourhoods with a median first‐episode TB incidence rate of 114 (IQR: 0–345) per 100,000 people. We found lower neighbourhood socioeconomic index (SEI), higher neighbourhood total TB burden, lower neighbourhood mean household size, and lower neighbourhood mean age were associated with increased neighbourhood first‐episode TB incidence. Our findings revealed a hotspot of first‐episode TB incidence in Cape Town and evidence of spatial dependency in the association between neighbourhood factors and TB incidence.Conclusion: Neighbourhood TB burden and SEI were associated with first‐episode TB incidence, and there was spatial dependency in this association. Our findings can inform targeted interventions to reduce TB in high‐risk neighbourhoods, thereby reducing health disparities and promoting health equity.


  • Open Access

    Aerosolization of viable Mycobacterium tuberculosis bacilli by tuberculosis clinic attendees independent of sputum-Xpert Ultra status

    by Benjamin Patterson, Ryan Dinkele, Sophia Gessner, Anastasia Koch, Zeenat Hoosen, Vanessa January, Bryan Leonard, Andrea McKerry, Ronnett Seldon, Andiswa Vazi, et al.

    Potential Mycobacterium tuberculosis ( Mtb ) transmission during different pulmonary tuberculosis (TB) disease states is poorly understood. We quantified viable aerosolized Mtb from TB clinic attendees following diagnosis and through six months’ follow-up thereafter. Presumptive TB patients (n=102) were classified by laboratory, radiological, and clinical features into Group A: Sputum-Xpert Ultra-positive TB (n=52), Group B: Sputum-Xpert Ultra-negative TB (n=20), or Group C: TB undiagnosed (n=30). All groups were assessed for Mtb bioaerosol release at baseline, and subsequently at 2 wk, 2 mo, and 6 mo. Groups A and B were notified to the national TB program and received standard anti-TB chemotherapy; Mtb was isolated from 92% and 90% at presentation, 87% and 74% at 2 wk, 54% and 44% at 2 mo and 32% and 20% at 6 mo, respectively. Surprisingly, similar numbers were detected in Group C not initiating TB treatment: 93%, 70%, 48% and 22% at the same timepoints. A temporal association was observed between Mtb bioaerosol release and TB symptoms in all three groups. Persistence of Mtb bioaerosol positivity was observed in ~30% of participants irrespective of TB chemotherapy. Captured Mtb bacilli were predominantly acid-fast stain-negative and poorly culturable; however, three bioaerosol samples yielded sufficient biomass following culture for whole-genome sequencing, revealing two different Mtb lineages. Detection of viable aerosolized Mtb in clinic attendees, independent of TB diagnosis, suggests that unidentified Mtb transmitters might contribute a significant attributable proportion of community exposure. Additional longitudinal studies with sputum culture-positive and -negative control participants are required to investigate this possibility.


  • Open Access

    Platelets of COVID-19 patients display mitochondrial dysfunction, oxidative stress, and energy metabolism failure compatible with cell death

    by Valentine Léopold, Osoul Chouchane, Joe M. Butler, Alex R. Schuurman, Erik H.A. Michels, Justin de Brabander, Bauke V. Schomakers, Michel van Weeghel, Daisy I. Picavet-Havik, Anita E. Grootemaat, et al.


  • Open Access

    The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O009-O155)

    by Sabine Hermans, Jurjen Versluis, Myriam Labopin, Sebastian Giebel, Yvette van Norden, Alexander Kulagin, Didier Blaise, Jean Diez Martin, Ellen Meijer, Montserrat Rovira, et al.